News

Daré Bioscience Engages Lincoln Park for $15 Million Investment

Daré Bioscience Engages Lincoln Park for $15 Million Investment

Daré Bioscience Secures $15 Million Stock Purchase Agreement

Daré Bioscience, Inc. (NASDAQ: DARE) is paving the way for innovative advancements in women’s health with a strategic move to enter a $15 million common stock purchase agreement with Lincoln Park Capital Fund, LLC. This agreement reflects Daré's dedication to enhancing healthcare outcomes and expanding treatment options for women.

Details of the Agreement

The terms of the stock purchase agreement grant Daré the flexibility to sell up to $15 million worth of its common stock to Lincoln Park over a span of 24 months. Crucially, the opportunity to sell these shares is contingent on the successful filing of a registration statement with the Securities and Exchange Commission (SEC). The management at Daré will exercise full control over the timing and quantity of shares sold, thereby ensuring that market conditions align with their strategic objectives.

Understanding the Financial Implications

Lincoln Park is obliged to purchase common stock sold under this agreement at prices determined by market conditions at the time of sale. This arrangement provides Daré with vital financial resources to drive forward its clinical programs and investigational products targeted at women's health issues. Importantly, there is no cap on the price per share that Lincoln Park might pay, ensuring the company's financial flexibility in this regard.

Harnessing the Proceeds for Product Development

In recent communications, Sabrina Martucci Johnson, President, and CEO of Daré Bioscience, expressed her enthusiasm regarding the partnership with Lincoln Park. The previous agreement with LPC in 2020 played a significant role in funding their successful Phase 3 study of XACIATO (clindamycin phosphate) vaginal gel 2%, which ultimately secured FDA approval. With the new infusion of capital, Daré aims to advance the development of critical treatments such as Sildenafil Cream, 3.6%, which shows promise in treating female sexual arousal disorder. This approach not only aligns with their overall strategy but also aims to enhance healthcare choices for women.

Regulatory Considerations

As part of the ongoing compliance framework, the securities offered to Lincoln Park under this agreement have not been registered under the Securities Act of 1933. Therefore, they cannot be offered or sold without appropriate registration or exemption from registration requirements. This aspect underscores Daré's commitment to adhering to regulatory standards while fostering innovative solutions in women's health.

About Daré Bioscience

Daré Bioscience is a frontrunner in the biopharmaceutical sector, focusing on developing pioneering products for women's health. The company's mission emphasizes the creation of a diverse array of therapeutic options that enhance women's health and overall well-being. Through their innovative portfolio, they aim to tackle various aspects of women's health, including reproductive health, menopause, and sexual health.

The launch of XACIATO™ is a cornerstone achievement for Daré Bioscience; this FDA-approved product caters to the treatment of bacterial vaginosis in women, and its distribution began following a licensing agreement with Organon. Daré's pipeline further includes Ovaprene®, a novel contraceptive option in development and Sildenafil Cream, 3.6%, which could potentially be a groundbreaking treatment for female sexual arousal disorder.

Acknowledgment and Recognition

Daré Bioscience continues to gain recognition within the biopharmaceutical community. They have not only made notable contributions to women's health but have also been recognized by industry publications for their leadership and innovation. In recent accolades, their CEO was honored as one of the most influential figures in the biopharmaceutical field, underpinning the company’s mission and commitment to positively impacting women's health.

In summary, the collaboration with Lincoln Park Capital represents a significant step for Daré Bioscience, as they harness these funds to propel their future developments in women's health. The responsible management of these resources will undoubtedly play a key role in advancing their clinical programs and bringing much-needed innovations to market.

Frequently Asked Questions

What is the significance of the $15 million agreement for Daré Bioscience?

The agreement allows Daré to access critical funds over the next two years, facilitating the advancement of their women's health initiatives and clinical studies.

How will Daré utilize the funds from the stock purchase agreement?

The funds are expected to support the development of ongoing projects such as Sildenafil Cream, 3.6%, which targets female sexual arousal disorder among other product candidates.

Who is Lincoln Park Capital Fund, LLC?

Lincoln Park Capital is an institutional investor based in Chicago, specializing in long-term equity investments across various sectors, including healthcare.

What products does Daré Bioscience have in its pipeline?

Daré’s pipeline includes XACIATO, Ovaprene, and Sildenafil Cream, addressing various aspects of women's health from contraception to treatment of sexual disorders.

How does Daré ensure compliance with SEC regulations?

Daré adheres to strict regulatory guidelines, including the filing of necessary documents and ensuring that securities offered are in line with compliance requirements.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 107

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 71

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 147

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
DISA Backs Nursing Education With OADN Foundation Push

Updated Category News Views 51

A nursing workforce does not appear by magic when hospitals need it most; somebody has to help students, instructors, and programs survive the long haul before that first shift. DISA's newly announced partnership with the Organization for Associate Degree Nursing and the OADN Foundation is aimed squarely at that unglamorous, essential stretch of the pipeline. For a sector...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 96

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 84

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 39

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 67

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
Avenir Nears 19.99% Grid Stake After Falcon West Resource

Updated Category News Views 76

Falcon West finally put enough geological meat on the bone to make Avenir reach for its wallet. Avenir Minerals expects to buy 29,388,127 Grid Metals common shares on or about November 30, 2026, taking its non-diluted position to 19.99%. That number is not accidental. It is the usual Canadian strategic-investor ceiling before the conversation starts getting considerably...

Continue Reading

Top 5 Most Recently Viewed Articles

Hyundai Unveils Palisade with John Krasinski for Epic Campaign

Updated Category News Views 223

Hyundai Launches 'Make Everyday Epic' Campaign Hyundai is thrilled to announce its latest marketing strategy highlighted by the Palisade Hybrid SUV, a vehicle designed to enrich everyday experiences. With its stunning aesthetics and performance capabilities, the Palisade emerges as a perfect choice for those seeking a touch of luxury in their daily activities. Epic...

Continue Reading
Olympus Corporation Updates Landscape with New CPT Codes

Updated Category News Views 238

Olympus Corporation Introduces New CPT Codes for ESD Olympus Corporation, a pioneering global medical technology company, has taken a significant step towards enhancing patient care in the realm of gastrointestinal health. Recently, the American Medical Association (AMA) announced the establishment of new Category I CPT codes for the Endoscopic Submucosal Dissection (ESD)...

Continue Reading
Audience Town's Conversion-Focused Tool Transforms Home Building

Updated Category News Views 156

Introducing Audience Town's New Tool for Home Builders Audience Town, a pioneering platform in home building performance analytics, has recently launched the Audience Targeting Add-On. This innovative tool marks a significant milestone for builders, providing them with the ability to retarget their highest-value website visitors effectively, effectively eliminating...

Continue Reading
Investor Class Action Alerts: Navigating Recent Legal Developments

Updated Category News Views 182

Investor Class Action Alerts: An Overview In today's marketplace, investors remain vigilant against various legal risks as class action lawsuits emerge against publicly traded companies. These lawsuits can significantly affect shareholders who are often left navigating complex legal landscapes. A recent reminder from The Law Offices of Frank R. Cruz regarding upcoming...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 261

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading